Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeEric J Miller, Matthew D. Galsky, Benjamin L. Maughan et al.|Cancer|2024Cited by 2